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A B S T R A C T   
Increased tissue content of long-chain acylcarnitines may induce mitochondrial and cardiac damage by stimu-
lating ROS production. N6-trimethyllysine dioxygenase (TMLD) is the first enzyme in the carnitine/acylcarnitine 
biosynthesis pathway. Inactivation of the TMLHE gene (TMLHE KO) in mice is expected to limit long-chain 
acylcarnitine synthesis and thus induce a cardio- and mitochondria-protective phenotype. TMLHE gene dele-
tion in male mice lowered acylcarnitine concentrations in blood and cardiac tissues by up to 85% and decreased 
fatty acid oxidation by 30% but did not affect muscle and heart function in mice. Metabolome profile analysis 
revealed increased levels of polyunsaturated fatty acids (PUFAs) and a global shift in fatty acid content from 
saturated to unsaturated lipids. In the risk area of ischemic hearts in TMLHE KO mouse, the OXPHOS-dependent 
respiration rate and OXPHOS coupling efficiency were fully preserved. Additionally, the decreased long-chain 
acylcarnitine synthesis rate in TMLHE KO mice prevented ischaemia-reperfusion-induced ROS production in 
cardiac mitochondria. This was associated with a 39% smaller infarct size in the TMLHE KO mice. The arrest of 
the acylcarnitine biosynthesis pathway in TMLHE KO mice prevents ischaemia-reperfusion-induced damage in 
cardiac mitochondria and decreases infarct size. These results confirm that the decreased accumulation of ROS- 
increasing fatty acid metabolism intermediates prevents mitochondrial and cardiac damage during ischaemia- 
reperfusion.   
1. Introduction 
The accumulation of long-chain acylcarnitines induces mitochon-
drial dysfunction during ischaemia-reperfusion, heart failure and 
inherited disorders [1–3]. In the fatty acid metabolism pathway, the 
long-chain acylcarnitines are the main players in ROS production [4]. 
The mitochondrial enzyme carnitine palmitoyltransferase (CPT) 1 ca-
talyses acylcarnitine synthesis from carnitine and long-chain acyl--
coenzyme A (CoA) and is a rate-limiting step in long-chain fatty acid 
transport and oxidation [5]. CPT1 activity is independent of mito-
chondrial metabolic status but is regulated by the AMP-activated protein 
kinase (AMPK) and insulin signalling pathways through changes in 
malonyl-CoA concentration [6]. Despite the limited mitochondrial 
metabolism of acylcarnitines in CPT2-coupled β-oxidation during 
ischaemia, intracellular signals still facilitate CPT1 activity and acyl-
carnitine synthesis [7]. This leads to an increase in long-chain acylcar-
nitine content in the mitochondrial intermembrane space [7]. A high 
level of long-chain acylcarnitines in the mitochondria inhibits oxidative 
phosphorylation and induces ROS production [4,7,8]. In addition, 
long-chain acylcarnitines at physiological concentrations inhibit the 
cardioprotective PI3K-Akt pathway, related glucose uptake and pyru-
vate oxidation in mitochondria [9,10]. To prevent disturbances in car-
diac metabolism, decreased long-chain acylcarnitine content is 
suggested as a potential treatment strategy for ischaemic heart disease 
[4,11]. 
Since carnitine is a substrate in acylcarnitine production, an effective 
strategy to inhibit the synthesis of long-chain acylcarnitines is a decrease 
in carnitine availability. Indeed, a reduced level of acylcarnitines was 
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observed in response to inhibited carnitine synthesis and transport [12, 
13]. Pharmacological interventions that prevent acylcarnitine accumu-
lation in various pathological states of mitochondrial dysfunction have 
been shown to reduce myocardial infarction, atherosclerosis and dia-
betes [12,14,15]. Similarly, CPT1 inhibition by oxfenicine treatment 
resulted in improved whole-body glucose tolerance and insulin sensi-
tivity in a diet-induced insulin resistance model [16]. Decreases in 
long-chain acylcarnitine content using genetically modified carnitine 
and acylcarnitine biosynthesis enzymes have never been used to verify 
the beneficial effects of decreased acylcarnitine levels. 
N6-trimethyllysine (TML) dioxygenase (TMLD) hydroxylates TML to 
3-hydroxy-TML [17]. TMLD is a nonheme ferrous-iron dioxygenase that 
requires 2-oxoglutarate, Fe2+ and molecular oxygen as cofactors [18]. 
TMLD was shown to localize in the mitochondrial matrix, and this 
enzyme is found in all tissues [19,20]. Since it is the first enzyme in the 
carnitine/acylcarnitine biosynthesis pathway, a decrease in TMLD ac-
tivity would lower the levels of all its reaction products and downstream 
metabolic intermediates, including long-chain acylcarnitines. Therefore, 
we developed constitutive whole-body TMLHE gene mutant (TMLHE 
KO) mice to confirm the hypothesis that reduced long-chain acylcarni-
tine content prevents mitochondrial and cardiac damage in cases of 
myocardial infarction. 
2. Materials and methods 
2.1. Development of TMLHE KO mice model 
The TMLHE KO mouse model was created in the Laboratory Animal 
Centre of Tartu University using the CRISPR/Cas9 gene-editing protocol 
to generate random mutations. Chemically modified CRISPR Revolution 
EZ sgRNA kit (TMLHE2.1 AGUUGUUGCACCAACAAAGC, Synthego 
Corporation, USA) and CRISPR Evolution Cas9 2NLS nuclease protein 
(Synthego Corporation) were used to target exon 2 of the TMLHE gene. 
Embryo electroporation (dpc 0.5 fertilized egg cells) was performed 
using an in-house validated protocol using a Nepagene Nepa21 elec-
troporator and a CUY501P1-1.5 electrode. Following electroporation 
parameters were used: Poring pulse: voltage - 50 V, pulse length - 2.5 ms, 
interval - 50 ms, number of pulses - 4, decay rate - 10%, polarity (+); 
Transfer pulse: voltage - 5 V, pulse length - 50 ms, interval - 50 ms, 
number of pulses - 5, decay rate - 40%, polarity (±). The resulting 
founder lines were analysed by pyrosequencing to detect random mu-
tations in exon 2 of the TMLHE gene. The most successful founder 
TMLHE knockout line had a deletion of 2 nucleotides, 103352 and 
103353, located on the second coding exon in the TMLHE gene 
(NT_165789 REGION: 251286..469175). Nucleotides missing in TMLH 
KO animals resulted in a frameshift and multiple STOP codons after the 
first 13 amino acid coding triplets. 
Male adult (8–12 weeks old) C57BL/6N mice (37 wild-type (WT) and 
37 TMLHE KO) were housed under standard conditions (21–23 ◦C, 
reversed 12-hr light/dark cycle, relative humidity of 45–65%) with 
unlimited access to food (R70 diet from Lantmännen) and water. Gen-
eration of the TMLHE knockout mouse line was approved by the Esto-
nian Project Authorisation Committee for Animal Experiments (No 103, 
22nd of May 2017). Studies were only performed with male mice to 
eliminate the possible confounding effects of reproductive hormones. 
The experimental procedures were performed in accordance with the 
guidelines of the European Community and local laws and policies 
(Directive 2010/63/EU), and all of the procedures were approved by 
Food and Veterinary Service, Riga, Latvia. All experiments were per-
formed in a blinded manner. Studies involving animals are reported in 
accordance with the ARRIVE guidelines [21]. 
2.2. TMLD activity assay 
TMLD activity was assayed by measuring the formation of 3-hy-
droxy-TML from TML in mouse liver mitochondria ex vivo. 
Mitochondria from the liver were isolated as described previously [22]. 
The reaction mixture (final volume of 0.2 ml) contained the following: 
20 mM potassium phosphate (pH 7.0), 20 mM potassium chloride, 3 mM 
2-oxoglutarate, 0.25 mM ferrous ammonium sulfate, 10 mM sodium 
ascorbate, 0.16 mg of catalase, 500 μM TML and 0.9 mg of mitochon-
drial protein. The reaction was initiated by the addition of mitochon-
dria, and the mixture was incubated at 37 ◦C for 2 h. The reaction was 
stopped by the addition of 0.2 ml of water and freezing in liquid nitro-
gen. Then, the mitochondria were lysed by 3 freeze-thaw cycles. After 
that, to perform deproteinization and extraction of HTML acetonitrile: 
methanol (1:3) was added and samples were centrifuged at 20000×g for 
10 min. HTML and TML levels were measured by ultra-performance 
liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) in 
positive ion electrospray mode [23]. 
2.3. Contents of GBB, carnitine and acylcarnitine 
The concentrations of γ-butyrobetaine (GBB) and carnitine in plasma 
samples were measured by UPLC-MS/MS using positive ion electrospray 
mode [12]. The acylcarnitine profile in heart tissue and plasma samples 
was determined by UPLC-MS/MS as previously described [24]. 
2.4. Metabolomics and lipidomics 
Metabolomic analysis was performed by Biocrates Life Sciences AG 
(Innsbruck, Austria), 630 metabolites were analysed in fed and over-
night fasted mouse plasma samples using LC-MS/MS and an MxP® 
Quant 500 kit. 
2.5. Fatty acid oxidation in isolated mice heart 
The rate of radiolabelled palmitate oxidation was measured in iso-
lated mouse hearts as previously described [25]. Briefly, mouse hearts 
were retrogradely perfused (perfusion pressure 70 mmHg) with the 
respective non-labelled oxygenated (95% O2, 5% CO2) Krebs-Henseleit 
(KH) buffer solution supplemented with 10 mM glucose, 0.3 mM so-
dium palmitate bound to 0.5% bovine serum albumin (BSA), 2 mM 
lactate, 0.2 mM pyruvate and 3 ng/ml insulin. After 20 min, the hearts 
were perfused with the respective oxygenated radiolabelled KH buffer 
solution for 10 min. The perfusate was collected to determine the fatty 
acid oxidation (FAO) rate by measuring the 3H2O released from [9, 
10-3H]-palmitate (specific activity, 60 Ci/mmol) using the method 
described previously [25]. 
2.6. Transthoracic echocardiography in mice 
The mice were anaesthetized using 5% isoflurane dissolved in oxy-
gen. After the onset of anaesthesia, the concentration of isoflurane was 
decreased to 2.0%, the experimental animals were then placed in a de-
cubitus position on a near-infrared heating pad to maintain body tem-
perature. The fur from the chest was removed using commercially 
available depilation cream (Veet®). M-mode tracings of the left 
ventricle were recorded at the level of papillary muscles with an iE33 
ultrasonograph equipped with a linear L15-7io transducer (Philips 
Healthcare, Andover, USA). 
2.7. Myocardial infarction assay 
Myocardial infarction was performed according to the Langendorff 
technique as described previously [26,27], with modifications required 
for mouse heart perfusion [28] as described below. The animals were 
anaesthetized with sodium pentobarbital (70 mg/kg), and heparin was 
administered intraperitoneally; after the loss of nociceptive reflexes, the 
hearts were immediately excised, sacrificing animals. Hearts were 
trimmed and mounted in the Langendorff system (ADInstruments) 
within 2 min of the excision. Hearts were retrogradely perfused with 
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oxygenated (95% O2, 5% CO2) KH buffer solution supplemented with 
10 mM glucose (Fresenius Kabi), 0.2% BSA (FA-free) (Life Science 
Production LSG Ltd), and 3 ng/ml insulin (Novo Nordisk) at a constant 
perfusion pressure of 70 mmHg. After catheter tubing (0.7 mm) was 
inserted in the left ventricle apex wall to aid fluid drainage [28], a 
water-ethanol mixture (1:1)-filled balloon connected to a physiological 
pressure transducer (ADInstruments) was inserted into the left ventricle, 
and the baseline end-diastolic pressure was set at 5–10 mmHg. After an 
adaptation period of 20 min, the left anterior descending coronary ar-
tery (LAD) was subsequently occluded (Surgipro II 5-0 suture placed 
through the heart around the LAD and tightened) for 20 min followed by 
120 min of reperfusion. Heart functional parameters: coronary flow, left 
ventricle developed pressure (LVDP), heart rate (HR) and cardiac 
workload were measured using the PowerLab system from ADInstru-
ments. Infarct size was determined as described previously [27]. Briefly, 
at the end of reperfusion, the LAD was reoccluded, and the heart was 
perfused with 0.1% methylene blue dissolved in KH buffer solution to 
delineate risk and no-risk areas. Afterwards, the ventricles of the heart 
were transversely cut into 1.5 mm thick slices (four) and photographed. 
Computerized planimetric analysis of the stained left ventricle slice 
photographs was performed using Image-Pro Plus v6.3 software to 
determine the area at risk and the area of necrosis, and each area was 
expressed as a percentage of the slice area. The obtained values were 
then used to calculate the infarct size as a percentage of the risk area. 
2.8. Mitochondrial functionality assessment 
The infarction study was performed as described above. Animals 
were anaesthetized with sodium pentobarbital (70 mg/kg), and heparin 
was administered intraperitoneally; after the loss of nociceptive reflexes, 
the hearts were immediately excised, sacrificing animals. The hearts 
were perfused with oxygenated (95% O2, 5% CO2) KH buffer solution 
supplemented with 10 mM glucose, 0.2% bovine serum albumin, and 3 
ng/ml insulin at a constant perfusion pressure of 70 mmHg. The isolated 
mouse hearts were adapted for 20 min, and the LAD was subsequently 
occluded for 20 min followed by shortened reperfusion for 60 min. After 
reperfusion, tissues were sectioned to obtain material from the risk area 
and non-risk area [27]. The permeabilized cardiac fibres were prepared 
from risk (ischaemic) areas and non-risk areas as described previously 
[29]. Mitochondrial respiration and H2O2 production measurements 
were performed at 37 ◦C using Oxygraph-2k (O2k; Oroboros In-
struments, Innsbruck, Austria) with O2k-Fluo-Modules in MiR05 me-
dium (110 mM sucrose, 60 mM K-lactobionate, 0.5 mM EGTA, 3 mM 
MgCl2, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, pH 7.1, 0.1% 
BSA (FA-free)). The medium was reoxygenated when the oxygen con-
centration decreased to 80 μM. H2O2 flux was measured simultaneously 
with respirometry in the O2k-Fluorometer using the H2O2-sensitive 
probe Ampliflu™ Red (AmR) as described [12]. The H2O2/O flux ratio 
[%] was calculated as the H2O2 flux/(0.5 O2 flux). 
Pyruvate and malate (5 mM and 2 mM, respectively) were used to 
determine NADH (N)-pathway, Complex I (CI)-linked LEAK respiration. 
Adenosine diphosphate (ADP) was added at a 5 mM concentration to 
determine oxidative phosphorylation-dependent respiration (OXPHOS 
state). Then, succinate (10 mM, Complex II (CII) substrate, S-pathway) 
was added to reconstitute convergent NS-pathway, CI- and CII-linked 
(CIII-linked) respiration. Then, an inhibitor of adenine nucleotide 
translocator (ANT), carboxyatractyloside (CATR), was added to deter-
mine LEAKCATR respiration. 
In addition, FAO-dependent mitochondrial respiration in cardiac fi-
bres was measured using palmitoylcarnitine (10 μM) and 0.5 mM malate 
as substrates. ADP was added to a concentration of 5 mM to assess 
respiration in the OXPHOS state. Pyruvate (5 mM, CI substrate, NADH 
(N)-pathway) was then added to reconstitute FN pathway-linked respi-
ration. Succinate (10 mM, CII substrate, S-pathway) was added to 
reconstitute convergent FNS-linked respiration. Then, rotenone (Rot) 
(0.5 μM, inhibitor of CI) and antimycin A (2.5 μM, inhibitor of CIII) were 
added to determine the S-linked respiration and residual oxygen con-
sumption (ROX), respectively. 
The OXPHOS coupling efficiency was calculated as follows: 
1 –
Resp.rate LEAK state
Resp.rate OXHOS state  
2.9. Preparation of cardiac muscle cells for assessment of mitochondrial 
ultrastructure 
Hearts were obtained from four WT and four KO anaesthetized and 
sacrificed animals following transcardial perfusion-based fixation to 
rapidly and uniformly preserve the tissue. Perfusion was performed with 
approximately 50 ml of 4% paraformaldehyde fixative for 10 min. The 
perfusion pressure was continuously maintained at 130 mmHg. Imme-
diately after perfusion fixation, the heart was isolated, cut into slices 
approximately 5 mm in thickness, and then into cubes with 1-mm sides. 
Then, the cubes were immersed in fixative containing 2.5% glutaral-
dehyde in 0.1 M cacodylate buffer for at least 24 h. Thereafter, the 
specimens were subjected to a standard preparation protocol where 
specimens were postfixed with 1% OsO4, stained en bloc with uranyl 
acetate in maleate buffer at pH 5.2, dehydrated with ascending con-
centrations of ethanol, infiltrated, and embedded in Epon resin, which 
was subsequently polymerized at 62 ◦C for 24 h. Semithin sections of 1 
μm thickness were cut and stained with 1% toluidine blue. Thereafter, 
ultrathin sections with a thickness of 60 nm were cut with an ultrami-
crotome (LKB Ultrotome V), mounted to 200-mesh copper grids, and 
double stained with 2% uranyl acetate in 70% methanol for 10 min, 
followed by lead citrate for 4 min. The specimens were imaged with a 
JEM 1011 JEOL (Japan) transmission electron microscope operating at 
100 kV. Cardiac muscle cells were examined at ×8000 - 30000 magni-
fication. Test fields were selected at a primary magnification of ×3000 
by systematic uniform random sampling. Images were captured at 
×8000 to analyse mitochondrial ultrastructure. For quantitative plani-
metric analysis, the imaged mitochondria were further analysed using 
Image-Pro Plus 6.3 software. 
2.10. Statistical methods and exclusion criteria 
Data are presented as the mean ± standard error of the mean (SEM). 
Based on data normality analysis, statistically significant differences in 
the mean values were evaluated using one-way ANOVA or the Kruskal- 
Wallis test. Based on data normality analysis, a t-test or the Mann 
Whitney test was used when only two groups were compared. If ANOVA 
or Kruskal-Wallis test yielded P < 0.05, Tukey’s or Dunn’s test was 
performed, respectively. Chi Square test was used for testing relation-
ships between categorical variables. The differences were considered 
significant when P < 0.05. The data were analysed using GraphPad 
Prism statistical software (GraphPad Inc., San Diego, CA, USA). The 
exclusion criterion for experiments using the Langendorff-perfused iso-
lated heart model was mounting time. Thus, if the heart could not be 
mounted within 4 min of excision, it was not included in the study. None 
of the hearts had to be excluded, as the mounting time was approxi-
mately 2 min. 
3. Results 
3.1. TMLHE KO mouse phenotype 
The genotype for each mouse was confirmed using PCR (Fig. S1). To 
evaluate changes induced by loss-of-function of the TMLHE gene, TMLD 
enzyme activity was compared in liver samples from WT and TMLHE KO 
mice. In WT mice, liver TMLD enzyme activity was approximately 7 μU/ 
mg prot, while in KO mice, liver TMLD was completely inactive 
(Fig. 1A). The absence of TMLD activity resulted in approximately by 
90% lower concentrations of GBB and carnitine in plasma (Fig 1BC). As 
a result of limited carnitine availability, short-, medium- and long-chain 
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acylcarnitine contents in the heart were significantly decreased by 86%, 
63% and 82%, respectively (Fig. 1E). The differences in the plasma 
acylcarnitine profile of KO and WT mice were the same (Fig. S2). The 
levels of plasma glucose, fatty acids and triglycerides in the plasma and 
liver were similar in WT and KO mice (Fig. S3). In addition, we 
compared the fatty acid oxidation rate in isolated intact mouse hearts of 
WT and KO mice. In KO animals, the [3H]-palmitate oxidation rate in the 
heart was significantly decreased by 35% (Fig. 1D). In the animal 
behavior tests, we observed that both muscular coordination and motor 
function of adult and aged (20 month old) KO mice are completely 
preserved (see supplementary video file). Overall, these measurements 
confirm that TMLHE gene mutation resulted in significantly lower 
acylcarnitine levels and a reduced risk of acylcarnitine accumulation in 
the mitochondria without any detrimental effects on muscle functions. 
3.1.1. The functionality of the intact heart in vivo and ex vivo 
To evaluate whether lower acylcarnitine levels and FAO rate influ-
ence cardiac functionality, anatomical and functional parameters of the 
left ventricle were assessed using echocardiography. As shown in 
Fig. S4, the ejection fraction (EF) and fractional shortening (FS) of the 
left ventricle were similar in both groups. The EFs in the control and 
TMLHE KO groups were 70 ± 1% and 68 ± 2%, respectively. The FS 
values in the control and TMLHE KO groups were 34 ± 1% and 33 ± 2%, 
respectively. Additionally, there were no differences in the thicknesses 
of the interventricular septum at end-systole (IVSs), interventricular 
septum at end-diastole (IVSd), left ventricular posterior wall at end- 
systole (LVPWs), and left ventricular posterior wall at end-diastole 
(LVPWd). Similarly, in Langendorff-perfused isolated hearts, the func-
tional parameters coronary flow, left ventricular developed pressure, HR 
and contractility (dp/dt max) were not significantly different between 
WT and TMLHE KO mice (Fig. S4). Overall, lower acylcarnitine levels 
and reduced FAO rate did not influence intact heart functionality in 
TMLHE KO mice. 
3.2. Metabolomic analysis 
In the metabolomics (lipidomics) analysis of plasma samples from 
fed and overnight fasted mice, the most significantly changed metabo-
lites in TMLHE KO mice were short-, medium-, and long-chain acyl-
carnitines (Fig. 2A). Additionally, according to whole lipidome data, 
lipids mostly consisting of saturated or monounsaturated FA were 
markedly decreased by up to 40% in TMLHE KO compared to WT mouse 
plasma, while lipids consisting of more than 6 double bonds were 
increased by up to 80% (Fig. 2B). Nevertheless, the total concentrations 
of lysophosphatidylcholine, phosphatidyl-cholines, sphingomyelins, 
ceramides, dihexosyl-ceramides, and cholesteryl esters were similar in 
WT and TMLHE KO mice (Fig. 2A). Thus, despite the same diet, in 
TMLHE KO mice, the lipid profile was markedly shifted to a significantly 
higher abundance of unsaturated FA (Fig. 2B). In the metabolome 
analysis of individual FA, we found increased concentrations of PUFAs 
in the plasma of TMLHE KO mice (Fig. 2B). In the fed TMLHE KO mice, 
plasma concentrations of eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA) were increased by approximately 35% (Fig. 2CD). In 
the fasted state, DHA and EPA concentrations in plasma were 1.5- and 
2.2-fold higher than those in the corresponding WT control group, 
respectively (Fig. 2CD). In contrast, the concentrations of palmitate and 
other non-esterified saturated FA in TMLHE KO mouse plasma were not 
higher than those in WT mouse plasma (Fig. 2E and Fig. S3). The mea-
surements of non-lipid metabolites showed significant approximately 
25% lower lactate and succinate concentrations in TMLHE KO mouse 
plasma (Fig. 2FG), indicating that mitochondrial metabolism of lactate/ 
pyruvate and the Krebs cycle were increased in response to the lower 
Fig. 1. Measurements of TMLD enzyme activity and GBB, carnitine, FAO and acylcarnitine concentrations in male WT and TMLHE KO mice. Liver TMLD 
enzyme activity was diminished in TMLHE KO mice compared to WT mice (A), and plasma concentrations of GBB (B) and carnitine (C) and cardiac contents of 
acylcarnitines (E) were significantly lower in KO mice. Overall cardiac fatty acid oxidation rate (FAO) was significantly lower in TMLHE KO mice (D). Each value is 
the mean ± SEM of 4–14 mice. *Significantly different from the WT group (Mann Whitney (A), t-test (B–E), P < 0.05). Abbreviations: TMLD, TML dioxygenase; GBB, 
γ-butyrobetaine; FAO fatty acid oxidation. 
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long-chain acylcarnitine levels in TMLHE KO mice. 
3.3. Myocardial infarction 
In the myocardial ischaemia-reperfusion experiment, the area at risk 
in both WT and TMLHE KO mouse hearts was on average 56–60% of the 
left ventricle (Fig. 3A). The infarct size in WT mouse hearts was 49 ±
4.7%; in comparison, in TMLHE KO mice, the infarct size was 30 ± 3.6%, 
significantly smaller than that in WT mice (Fig. 3B). Thus, the hypoth-
esis that a lower cardiac content of long-chain acylcarnitine levels is 
cardioprotective is confirmed for the first time in a genetic mouse model. 
The heart functional parameters of isolated Langendorff-perfused 
hearts from TMLHE KO mice were similar to those hearts from WT 
mice (Fig. 3CD). Cardiac flow in the intact isolated heart was approxi-
mately 2 ml/min in both WT and TMLHE KO mice. Additionally, the 
LVDP, and the HR was similar in both groups (Fig. 3CD). Accordingly, 
cardiac work was similar in hearts isolated from TMLHE KO mice and 
WT mice. Coronary flow during LAD occlusion was decreased by 45% in 
the WT control mouse group and by 51% in the TMLHE KO mouse 
group. During reperfusion, coronary flow recovered up to 90% from 
baseline in the WT group and up to 115% in the TMLHE KO group, 
although this difference was not statistically significant. No significant 
differences were observed in LVDP, HR, or cardiac workload between 
the WT and TMLHE KO mouse groups during occlusion and reperfusion 
(Fig. 3CD). 
3.4. Mitochondrial function 
If compared with WT mice, in the cardiac fibres isolated from the 
non-risk area of TMLHE KO mouse hearts, the carnitine-independent 
CPT2-coupled β-oxidation of long-chain acylcarnitines as well as the 
pyruvate (N) or pyruvate and succinate (NS) pathway-linked respiration 
rate in the OXPHOS state was higher by 24–46% (Fig. 4AB); however, 
there was no difference in FAO-dependent and NS pathway-dependent 
OXPHOS coupling efficiency between TMLHE KO and WT animals 
(Fig. 4CD). In addition, under normoxic conditions, a similar rate of 
mitochondrial ROS production (H2O2/O ratio) was observed in both 
groups in all of the studied states and pathways (Fig. 4EF). These results 
indicate that limited carnitine availability in TMLHE KO animals does 
not inhibit but rather stimulates mitochondrial bioenergetics related to 
pyruvate and fatty acid metabolism. 
Ischaemia-reperfusion induced significant disturbances in 
Fig. 2. Metabolomics analysis of male WT and TMLHE KO mice plasma. In total, 630 metabolites were analysed in WT and TMLHE KO mouse plasma samples 
using LC-MS/MS and the MxP® Quant 500 kit (Biocrates). The lipid metabolite profile presented as a heatmap (A) showed differences in acylcarnitine and PUFA 
concentrations and a global shift in FA content from saturated to unsaturated lipids (B). EPA (C) and DHA (D) concentrations in plasma were significantly higher in 
TMLHE KO mice in the fasted state than in the other groups, instead palmitate concentrations were significantly lower in TMLHE KO mice in the fed state (E). Lactate 
(F) and succinate (G) concentrations were lower in TMLHE KO mice in both states. Data are expressed as heatmap (values of metabolite concentrations were 
normalized to WT fed group) and as the mean ± SEM (n = 9 in each group). *Significantly different from the WT group in the fed state. #Significantly different from 
the WT group in the fasted state (Kruskall-Wallis test followed by Dunn’s multiple comparisons test P < 0.05). Abbreviations: DAG, Diacylglycerols; EPA, eicosa-
pentaenoic acid; DHA, docosahexaenoic acid. 
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mitochondrial functionality in WT mouse hearts. In cardiac fibers iso-
lated from the risk area of WT mouse left ventricles, FAO-dependent and 
FN pathway respiration were decreased by approximately 75% 
(Fig. 4AB), while N- and NS-linked OXPHOS-dependent respiration rates 
were decreased by 73% and 52% (Fig. 4B), respectively. Moreover, in 
fibers from the risk area of WT animals, a significant 58% reduction in 
NS pathway-dependent OXPHOS coupling efficiency was observed 
(Fig. 4D), while in FAO-dependent OXPHOS, coupling efficiency tended 
to be decreased by 33% (p = 0.12). (Fig. 4C). As indicated by the H2O2/ 
O ratio in WT animal cardiac fibers after ischaemia-reperfusion, the 
production of mitochondrial ROS in the OXPHOS state was increased by 
3–13 times compared to fibers isolated from a non-risk area of the heart 
(Fig. 4EF). 
In the risk area of KO mouse hearts, N- and NS-linked OXPHOS- 
dependent respiration rates, as well as OXPHOS coupling efficiency, 
were preserved under ischaemia-reperfusion damage (Fig. 4BD). 
Moreover, the H2O2/O ratio was significantly lower (on average, 2.3 
times) in the FAO-, N- and NS-linked OXPHOS state in TMLHE KO risk 
areas compared to those in WT mice (Fig. 4EF). Taken together, these 
results indicate that in TMLHE KO mice, cardiac mitochondrial func-
tionality is protected from ischaemia-reperfusion-induced damage. 
Overall, lower carnitine bioavailability combined with stimulated 
acylcarnitine utilization in mitochondria results in low levels of acyl-
carnitines and a lower risk of long-chain acylcarnitine-induced mito-
chondrial damage. 
Fig. 3. Area at risk (A), infarct size (B), represen-
tative images of TTC-stained heart slices and the 
heart functional parameters LVDP (C) and heart 
rate (D) of male WT and TMLHE KO mice. Infarct 
size was determined in a Langendorff-perfused iso-
lated heart ischaemia-reperfusion model. Data are 
expressed as the mean ± SEM (n = 11–13 in each 
group). Cardiac parameters were not recorded for 2 
hearts in the KO group due to sensor failure *p < 0.05 
vs. the corresponding WT control mice (t-test). Ab-
breviations: LV, left ventricle; LVDP, left ventricle 
developed pressure; TTC, triphenyl tetrazolium 
chloride.   
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3.5. Ultrastructure of cardiomyocyte mitochondria 
Since TMLD is a mitochondrial enzyme, the ultrastructural organi-
zation of the organelle was examined by transmission electron micro-
scopy in both WT and TMLHE KO animals. No apparent ultrastructural 
changes in cardiac muscle cells were observed in TMLHE KO animals 
compared with WT mice. The numerous mitochondria were arranged in 
rows and interspersed by tightly packed contractile filaments that 
appeared to be thick myosin and thin actin filaments. In addition, 
cisternae of the smooth endoplasmic reticulum were near the outer 
mitochondrial membrane. The outer and inner mitochondrial mem-
branes were intact, the intermembrane space was narrow, numerous 
lamellar cristae were densely packed, and the density of the matrix was 
moderate (Fig. 5A). Differently shaped and sized mitochondrial profiles 
were demonstrated in thin sections. Furthermore, according to quanti-
fication analyses, significantly more mitochondrial profiles per micro-
scopic field were observed in cardiac muscle cells of TMLHE KO mice 
than in those of WT mice (Fig. 5B). Simultaneously, the mitochondrial 
area calculated for cardiac muscle cells was similar in WT and TMLHE 
KO mice (Fig. 5C). Finally, a significantly increased percentage of small 
mitochondria and a decreased percentage of large mitochondria were 
observed in the cardiac muscle cells of TMLHE KO mice compared to 
those of WT mice (Fig. 5D). Citrate synthase activity and the amount of 
mitochondrial DNA (Fig. 5EF), as well as the expression level of mito-
chondrial biogenesis and fission- and fusion-related genes, were similar 
in TMLHE KO and WT mouse hearts (Fig. S5). Taken together, these data 
demonstrate that deletion of mitochondrial TMLHE slightly increases 
the number of small mitochondria but does not substantially change 
mitochondrial biogenesis, fission-fusion, morphology, or organization in 
the heart. 
4. Discussion 
The inactivity of the TMLD enzyme in TMLHE KO mice resulted in an 
substantially lower long-chain acylcarnitine content in plasma and in 
the heart. Limited acylcarnitine biosynthesis induced a partial decrease 
in the cardiac FAO rate by 35% and a subsequent increase in the plasma 
concentrations of PUFAs but not saturated fatty acids. Other measures of 
Fig. 4. Mitochondrial respiration rate (AB), OXPHOS coupling efficiency (CD), and mitochondrial ROS production (EF) in permeabilized cardiac fibers 
from normoxic non-risk and reperfused areas in at-risk regions of the male mice heart. Each value represents the mean ± SEM of 6 mice. *Significantly 
different from the respective WT control (NR or R) group (t-test, P < 0.05). #Significantly different from the respective normoxic (NR) group (t-test, P < 0.05). 
Abbreviations: PC, palmitoylcarnitine; FAO, fatty acid oxidation; OXPHOS, oxidative phosphorylation-dependent state; LEAK/LEAKN, substrate metabolism- 
dependent state without adenylates; LEAKT, LEAK in presence of ATP; D, ADP; PM, pyruvate and malate; FAO dependent pathway; N, NADH pathway; S, succi-
nate pathway; Ama, Antimycin A; ROX, residual oxygen consumption; Catr, carboxyatractyloside; Rot, rotenone. 
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Fig. 5. Qualitative and quantitative assessment of mitochondrial ultrastructure. Representative transmission electron microscopy images of mitochondrial 
morphology in cardiac muscle cells of male WT and TMLHE KO mice (A). Electron micrographs of the cardiac muscle cells of both WT (left panel) and TMLHE KO 
(right panel) mice depict well-preserved mitochondrial features such as intact membranes and regularly organized cristae. Scale bars: 1 μm (200 nm, inserts). 
Mitochondrial morphology was assessed in cardiac muscle cells of WT and TMLHE KO mice and expressed as the average number of mitochondrial profiles per 
microscopic field (B). Mitochondrial area assessed per microscopic field in cardiac muscle cells of WT and TMLHE KO mice (C). Frequency of distribution according 
to size demonstrated in cardiac muscle cells of WT and TMLHE KO mice when an average value for the mitochondrial area was considered (D). If the square of a 
single mitochondrial profile exceeded 1000 μm2, it was considered large, whereas if the square of a single profile was less than 250 μm2, it was considered small. The 
amount of mitochondria was compared by measuring mitochondrial citrate synthase activity (E) and the amount of mitochondrial DNA (F) in the hearts of WT and 
KO mice. Mito ‒ mitochondrion. Bars represent mean ± SEM. * Significantly different from the WT group (t-test (A), Chi-squared test (D), P < 0.05). Abbreviations: 
Cox1, Cytochrome c oxidase I; ND4, NADH dehydrogenase 4. 
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metabolic phenotype, mitochondrial number and morphology, and 
cardiac mechanic functionality were similar in TMLHE KO and WT mice. 
In the state of decreased acylcarnitine content, TMLHE KO mouse car-
diac mitochondria have significantly better preserved functionality and 
a lower ROS production rate during ischaemia-reperfusion than WT 
mouse cardiac mitochondria. This coincided with a smaller infarct size 
in the TMLHE KO mice. 
It has been demonstrated that long-chain acylcarnitines accumulate 
in the heart and substantially contribute to cardiac damage during 
ischaemia and reperfusion [7,13,30]. Thus far, the lowering of 
long-chain acylcarnitine levels has been achieved by pharmacological 
agents [12,26] that might have some off-target actions. In this study, a 
lower acylcarnitine content was achieved through genetic manipulation, 
and the absence of TMLD-driven acylcarnitine biosynthesis was associ-
ated with a 39% smaller infarct size in TMLHE KO mice than in WT mice. 
This is in line with previous studies showing the beneficial effect of 
reduced long-chain acylcarnitine content by pharmacological agents 
[12,26]. In the metabolomic analysis, a several-fold reduction in acyl-
carnitine content was the most prominent difference among more than 
600 metabolites measured in TMLHE KO and WT mice. Thus, the effect 
on acylcarnitine content could be considered the main mechanism 
responsible for the cardioprotective effect in TMLHE KO mice. Addi-
tionally, the novel finding of this study is increased levels of unsaturated 
fatty acids, in particular, PUFAs, in TMLHE KO animals. Thus the 
decreased long-chain acylcarnitine production rate increases PUFA 
levels in TMLHE KO mice. It is widely accepted that the reduced risk of 
cardiovascular disease and type 2 diabetes, as well as other beneficial 
effects on health are observed when dietary saturated FA are replaced 
with PUFA [31]. The shift from saturated to unsaturated fatty acid 
content as well as a marked increase in DHA and EPA levels may be 
partially responsible for the cardioprotective phenotype in TMLHE KO 
mice. 
During ischaemia, long-chain acylcarnitines are excessively gener-
ated, accumulate in mitochondria, and induce marked impairment in 
mitochondrial functionality [8,32]. In this study, in WT animals, we also 
found substantial OXPHOS inhibition in cardiac mitochondria from the 
area at risk. These unfavourable effects on mitochondria are typical for 
increased levels of long-chain acylcarnitines [7]. In contrast, in the risk 
area of TMLHE KO mouse hearts, the OXPHOS-dependent respiration 
rate and OXPHOS coupling efficiency were fully preserved against 
ischaemia-reperfusion damage. Thus, the reduced acylcarnitine 
biosynthesis rate in TMLHE KO mouse heart mitochondria prevents the 
accumulation of long-chain acylcarnitines and corresponding damage. 
This also confirms that long-chain acylcarnitine accumulation contrib-
utes to substantial mitochondrial damage during ischaemia-reperfusion. 
The effect on FAO-dependent respiration in the ischaemic area of 
TMLHE KO mouse heart mitochondria was somewhat less pronounced. 
It could be explained by the observation that oxygen consumption in the 
risk area of WT animal hearts is not fully coupled with oxidative phos-
phorylation and a part of oxygen is wasted for the formation of ROS. In 
KO animals ROS production is significantly reduced and coupling effi-
ciency is significantly improved. Also, the decrease in CPT2-linked 
β-oxidation is partially caused by ischaemia-induced free CoA defi-
ciency in mitochondria, which could be only partially prevented in the 
case of lower levels of acylcarnitines. Also, the decrease in CPT2-linked 
β-oxidation is partially caused by ischaemia-induced free CoA deficiency 
in mitochondria, which could be only partially prevented in the case of 
lower levels of acylcarnitines. Importantly, ROS production was simi-
larly decreased in FAO-, pyruvate- and pyruvate & succinate 
metabolism-linked pathways, supporting the difference in the OXPHOS 
states of TMLHE KO and WT mice. This finding confirms the essential 
role of long-chain acylcarnitines in ROS induction during reperfusion. 
Taken together, these results suggest that long-chain acylcarnitines 
significantly contribute to mitochondrial functional disturbances, and a 
decrease in long-chain acylcarnitines prevents 
ischaemia-reperfusion-induced mitochondrial damage. 
Carnitine is considered a pivotal molecule for the function of energy 
metabolism pathways [33]. In humans, primary carnitine deficiency is a 
rare autosomal recessive disorder most frequently caused by defective 
carnitine transport [34,35]. Impaired carnitine transport depletes 
long-chain fatty acid oxidation in mitochondria and can result in skeletal 
muscle myopathy and cardiomyopathy [35,36]. However, TMLD defi-
ciency in humans is not causing any severe phenotype despite lower 
levels of GBB and carnitine [35,37]. In this study, limited carnitine 
availability in TMLHE KO mice reduced the fatty acid oxidation rate in 
the heart only by 35%; however, mitochondrial respiration via both 
pyruvate and palmitoylcarnitine was increased. This suggests that 
mitochondrial metabolism was enhanced through both main metabolic 
pathways. In the metabolomic analysis, we found lower levels of ace-
tylcarnitine, lactate, and succinate, suggesting the complete mitochon-
drial metabolism [38,39] of energy substrates, while mitochondrial 
morphology, biogenesis, and fission-fusion were similar in WT and 
TMLHE KO mice. Importantly, despite the lower fatty acid oxidation 
rate, the cardiac functionality of TMLHE KO mice was unchanged, as 
evidenced by measurements in isolated heart experiments and echo-
cardiography examinations in vivo. In addition, we observed completely 
preserved muscular coordination and motor function in the rotarod test 
of adult and aged (20-month-old) TMLHE KO mice (Supplementary 
video). Overall, a lower level of long-chain acylcarnitines before 
ischaemia in TMLHE KO optimizes pyruvate metabolism, β-oxidation, 
and Krebs cycle functioning, ensuring the complete metabolism of en-
ergy substrates and proper heart and muscle function. 
TML and GBB are substrate and product of the TMLD enzyme, 
respectively. They are known mostly as bio-precursors of carnitine, 
while GBB availability is considered a limiting factor for carnitine 
biosynthesis [40]. To date, there are very few studies related to the 
physiological and pharmacological properties of GBB and TML. The 
metabolites of carnitine and GBB were first investigated for 
acetylcholine-like activity decades ago [41], but later, it was shown that 
the methyl ester of GBB but not GBB itself exerts its biological activity by 
binding to muscarinic acetylcholine receptors [42]. Recently, it was 
found that serum levels of TML, GBB, and long-chain palmitoylcarnitine 
predict the long-term risk of type 2 diabetes independently of traditional 
risk factors, possibly reflecting dysfunctional fatty acid metabolism in 
subjects susceptible to type 2 diabetes development [43]. In a study by 
Schooneman, GBB supplementation did not facilitate FAO and did not 
prevent impaired glucose homeostasis in HFD-fed mice [44]. In this 
study, up to a 10-fold decrease in GBB plasma concentration was 
observed in TMLHE KO mice, which led to lower levels of carnitine and 
acylcarnitines. However, except for the role of precursors of carnitine 
and following acylcarnitine synthesis, we cannot currently link TML and 
GBB to any other biochemical changes in TMLHE KO mice. 
In conclusion, genetic inactivation of the TMLD enzyme in TMLHE 
KO mice resulted in significantly lower acylcarnitine content and a 
partial decrease in the cardiac FAO rate. In the plasma metabolome of 
TMLHE KO mice, mainly GBB, carnitine, and acylcarnitine levels were 
decreased, while PUFA concentrations were significantly increased. In 
the state of decreased long-chain acylcarnitine content, TMLHE KO 
mouse cardiac mitochondria have significantly preserved functionality 
and a lower ROS production rate after ischaemia-reperfusion than WT 
mice. Accordingly, loss of TMLD activity is associated with a signifi-
cantly smaller infarct size in TMLHE KO mice and points to TMLD as a 
novel target for cardioprotective therapies. 
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